Novo Nordisk Drops Price of Weight-Loss Drug Wegovy
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
Novo Nordisk will slash the price of its blockbuster weight-loss drug Wegovy for cash-paying patients, after American rival Eli Lilly discounted some of its Zepbound injections last week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results